Iradimed (IRMD) Net Income towards Common Stockholders (2013 - 2026)

Iradimed (IRMD) has 14 years of Net Income towards Common Stockholders data on file, last reported at $5.8 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $5.8 million, up 24.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.6 million (up 19.34% YoY), and the FY2025 annual result was $22.5 million, up 16.88% from the prior year.
• Net Income towards Common Stockholders retreated to $5.8 million in Q1 2026 per IRMD's latest filing, from $6.4 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $6.4 million in Q4 2025 and troughed at $2.5 million in Q1 2022.
• A 5-year average of $4.5 million and a median of $4.7 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders soared 120.53% in 2022, then dropped 15.13% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $3.7 million in 2022, then declined by 15.13% to $3.1 million in 2023, then soared by 65.08% to $5.1 million in 2024, then increased by 25.17% to $6.4 million in 2025, then slipped by 9.69% to $5.8 million in 2026.
• Business Quant data shows IRMD's Net Income towards Common Stockholders at $5.8 million in Q1 2026, $6.4 million in Q4 2025, and $5.6 million in Q3 2025.